News and Announcements
Jeremy Britton of Boston Trading Co.
- Published December 06, 2022 11:36PM UTC
- Publisher Maan Perez
- Categories Executive Interviews
Boston Trading Co. is a diversified crypto fund (Bostoncoin) that provides easy access to crypto for individuals, retail investors, and retirement funds. Investors have received returns of 366% per year on average for four years in a row, outperforming Bitcoin for six years. Since 2016, the Bostoncoin portfolio has included 30 to 50 crypto tokens plus tech stocks, making it easier for investors to have a safe and secure diversified crypto portfolio.
Watch this interview with CFO Jeremy Britton to learn more about the crypto fund’s competitive advantage compared to other existing funds.
Executive Interviews
12.25% Total Returns? This Trust’s Fuel and Convenience Strategy Is Pumping Up Profits
The Queensland Property Strategy Turning Heads—And Profits In the world of commercial property investment, finding the next big opportunity is like striking gold. And right now, there’s a gold rush happening in Queensland, with Amplify, a Queensland-based Funds Manager, leading the charge. Let’s cut through the noise and see what’s really going on. The Amplify […]
A Nation Divided: Insights from Our Subscriber Poll on the Upcoming U.S. Election
October 20, 2024 This entire post was created by ChatGPT o1 utilising the data and comments from the poll. The world watches closely as the United States stands on the brink of a consequential presidential election. The outcome will shape America’s future and have profound implications for the global economy and international relations. To capture […]
A New Era of Investment in Australia’s Life Science Sector
In just six months, four new investment funds have emerged, all targeting Australia’s life sciences and healthcare companies. With scientific advancements, government backing, and structural undervaluation, these funds represent a significant moment for the sector—offering investors a rare opportunity to capitalise on growth in biotech and medtech.
Backed By Leading Investment Groups and Family Offices
